HGH Fragment 176-191: adverse events and evidence limits
The Longeva listing describes unmodified HGH Fragment 176-191 as a 5 mg lyophilized powder [1]. Its native sequence, FLRIVQCRSVEGSCGF, differs from AOD9604 (YLRIVQCRSVEGSCGF) at the first residue: phenylalanine instead of tyrosine [2][4]. This compares the named compounds and does not verify a particular batch.
The inspected 1978 primary abstract includes synthetic 176-191 among peptides causing a brief glucose rise and a longer insulin rise in normal rats. It also reports reduced insulin sensitivity after a single 5 nmol/kg exposure to active fragments. The abstract leaves peptide administration route unstated; its intravenous wording describes the insulin-tolerance test [3].
A separate report of intravenous and oral AOD9604 describes severe chest tightness and a serious adverse event, diarrhoea, as possibly treatment-related [4]. These concern another molecule and studied formulations. The inspected sources cannot estimate clinical adverse-reaction incidence or establish safety of the current native fragment; the exposure stated here is study context, not a recommendation [1][2][3][4].
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Brief glucose rise | Normal rats; synthetic C-terminal growth-hormone fragments, including 176-191 | Observed; a metabolic measurement in an animal model — no clinical frequency established | [3] |
| Longer insulin rise and reduced insulin sensitivity | The same rats; reduced sensitivity after a single 5 nmol/kg exposure to active fragments | Observed; hormonal measurements that provide no human clinical adverse-event frequencies | [3] |
| Severe chest tightness; serious diarrhoea | Humans; AOD9604 (a different molecule), intravenous and oral | Described as possibly treatment-related; these are data on another molecule, not the native 176-191 fragment, and establish no frequency for it | [4] |
References
- Longeva (2026). Public HGH Fragment 176-191 listing https://longeva.bio/ua/product/hgh-fragment-176-191.
- L. Chantalat; N. D. Jones; F. Korber; J. Navaza; A. G. Pavlovsky (1995). HUMAN GROWTH HORMONE; associated citation: The crystal-structure of wild-type growth-hormone at 2.5 Angstrom resolution. https://www.rcsb.org/structure/1HGU.
- F. M. Ng; J. Bornstein (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone https://pubmed.ncbi.nlm.nih.gov/645904/ doi:10.1152/ajpendo.1978.234.5.E521.
- Heike Stier; Evert Vos; David Kenley (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans https://jofem.org/index.php/jofem/article/view/157/194 doi:10.4021/jem157w.